[1]常孟洁,张丽霞,袁清茹,等.宁心活血祛痰汤辅助治疗急性冠脉综合征患者PCI术后心绞痛的临床效果及其对血清vWF、CD62p水平的影响▲[J].内科,2020,15(06):650-653.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.05]
 CHANG Mengjie,ZHANG Lixia,YUAN Qingru,et al.Clinical effect of Ningxin Huoxue Qutan decoction in the adjuvant treatment of angina pectoris after PCI in patients with acute coronary syndrome and its effects on serum vWF and CD62p levels[J].Internal Medicine of China,2020,15(06):650-653.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.05]
点击复制

宁心活血祛痰汤辅助治疗急性冠脉综合征患者PCI术后心绞痛的临床效果及其对血清vWF、CD62p水平的影响▲()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年06
页码:
650-653
栏目:
论著
出版日期:
2020-12-31

文章信息/Info

Title:
Clinical effect of Ningxin Huoxue Qutan decoction in the adjuvant treatment of angina pectoris after PCI in patients with acute coronary syndrome and its effects on serum vWF and CD62p levels
文章编号:
1673-7768(2020)06-0650-04
作者:
常孟洁1张丽霞2袁清茹1张国芳1高颖1
1 郑州市第九人民医院心内科,河南省郑州市450000;2 郑州市惠济区人民医院普内科,河南省郑州市450000
Author(s):
CHANG Mengjie1 ZHANG Lixia2 YUAN Qingru1 ZHANG Guofang1 Gao Ying1
1 Department of Cardiology, Zhengzhou Ninth People′s Hospital, Zhengzhou 450000, Henan Province, China; 2 Department of General Internal Medicine, Huiji District People′s Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China
关键词:
急性冠脉综合征心绞痛宁心活血祛痰汤经皮冠状动脉介入术P选择素血管性血友病因子
Keywords:
Acute coronary syndrome Angina pectoris Ningxin Huoxue Qutan decoction Percutaneous coronary intervention P-selectin Von Willebrand factor
分类号:
R 543.3
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2020.06.05
文献标志码:
A
摘要:
目的探讨宁心活血祛痰汤辅助治疗急性冠脉综合征(ACS)患者经皮冠状动脉介入术(PCI)术后心绞痛的临床效果及对患者血清血管性血友病因子(vWF)、P选择素(CD62p)水平的影响。方法选择2018年2月至2020年2月在我院治疗的ACS患者84例,采用随机数字表法分为两组,每组42例。对照组患者给予PCI术及常规治疗,实验组患者在此基础上,加用宁心活血祛痰汤辅助治疗,疗程2个月。比较两组患者的临床疗效;比较两组患者治疗前后的vWF、CD62p、糖蛋白(GP)Ⅱb/Ⅲa受体复合物水平。结果实验组患者的治疗总有效率(90.48%)显著高于对照组(71.43%),差异有统计学意义(P<0.05)。治疗前,两组患者的血清vWF、P选择素CD62p、GP Ⅱb/Ⅲa受体复合物水平比较,差异无统计学意义(P>0.05);治疗2个月后,实验组患者的血清CD62p、vWF、GPⅡb/Ⅲa受体复合物水平显著低于对照组,差异有统计学意义(P<0.05)。治疗过程中,两组患者的肝肾功能、尿常规、血常规无明显异常,无明显不良反应发生。结论宁心活血祛痰汤辅助治疗能有效改善ACS患者PCI术后的心绞痛病情,改善患者血管内皮细胞功能和血小板活性,治疗安全性高。
Abstract:
ObjectiveTo explore the clinical effect of Ningxin Huoxue Qutan decoction in the adjuvant treatment of angina pectoris after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS), and its effects on serum von Willebrand factor (vWF) and P-selectin (CD62p) levels. MethodsA total of 84 ACS patients who were treated in our hospital from February 2018 to February 2020 were selected, and they were divided into two groups by the random number table method, with 42 cases in each group. Patients in the control group were treated with PCI and conventional treatment, based on which patients in the experimental group were additionally treated with Ningxin Huoxue Qutan decoction as the adjuvant treatment, for a two-month treatment course. The clinical efficacy, the serum levels of vWF, CD62p and glycoprotein (GP) Ⅱb/Ⅲa receptor complex before and after treatment were compared between the two groups. ResultsThe total effective rate of treatment in the experimental group (90.48%) was significantly higher than that in the control group (71.43%), and the difference was statistically significant (P<0.05). There were no statistically significant differences in the levels of serum vWF, P-selectin CD62p, GP Ⅱb/Ⅲa receptor complex between the two groups before treatment (P>0.05). The serum CD62p, vWF, and GPⅡb/Ⅲa receptor complex levels of the experimental group were significantly lower than those of the control group after 2 months of treatment, and the differences were statistically significant (P<0.05). There were no obvious abnormalities in liver and kidney function, urine routine and blood routine of the two groups, and no obvious adverse reactions occurred during the treatment. ConclusionThe adjuvant treatment of Ningxin Huoxue Qutan decoction can effectively improve the angina pectoris of ACS patients after PCI, improve the function of vascular endothelial cells and platelet activity in patients. And thus it is highly safe for treatment.

相似文献/References:

[1]孙文静 徐戈*.不同剂量阿托伐他汀短期治疗对急性冠脉综合症患者PCI围手术期血浆sCD163的影响[J].内科,2014,(03):252.
 SUN Wen-jing,XU Ge*.The effect of different doses of short-term atorvastatin on the concentration of plasma sCD163 in patients with acute coronary syndrome during perioperative period of PCI[J].Internal Medicine of China,2014,(06):252.
[2]韦文林 李锦忠 农善华 王英杰.急性冠脉综合征患者β内啡肽和血清脑利尿钠肽的变化及临床意义[J].内科,2014,(03):268.
 WEI Wen-lin,LI Jin-zhong,NONG Shan-hua,et al.Study on changes and clinical significance of beta endorphin and serum brain natriuretic peptide in patients with acute coronary syndrome[J].Internal Medicine of China,2014,(06):268.
[3]覃慈.参麦注射液联合舒血宁治疗冠心病心绞痛103例疗效观察[J].内科,2013,(06):590.
 [J].Internal Medicine of China,2013,(06):590.
[4]潘秀贤,蔡焕荣,李兵.急性冠脉综合征患者血液流变学及超敏C反应蛋白变化分析[J].内科,2010,(01):16.
 [J].Internal Medicine of China,2010,(06):16.
[5]潘秀贤,罗林玲,李兵.急性冠脉综合征患者胆固醇、总胆汁酸及总胆红素检测的临床意义▲[J].内科,2010,(03):233.
 PAN Xiu-xian,LUO Lin-ling,LI Bing.Clinical significance of detection of cholesterol, total bile acid and total bilirubin in patients with acute coronary syndrome[J].Internal Medicine of China,2010,(06):233.
[6]王纲.非ST段抬高急性冠脉综合症介入治疗临床观察[J].内科,2010,(03):259.
 [J].Internal Medicine of China,2010,(06):259.
[7]唐秀革,花冠杰,韦利元,等.绝经后急性冠脉综合征患者雌激素水平与血脂及内皮素-1水平的关系[J].内科,2010,(05):460.
 TANG Xiu-ge,HUA Guan-jie,WEI Li-yuan,et al.The relationship between blood estrogen,lipoproteins and endothelin-1 in post-menopausal women with acute coronary syndrome[J].Internal Medicine of China,2010,(06):460.
[8]覃小梅,谭晓明,曾显媛.急性冠脉综合征患者总胆红素、胆汁酸及血尿酸水平分析[J].内科,2010,(06):590.
 [J].Internal Medicine of China,2010,(06):590.
[9]黄海英.盐酸替罗非班在急性冠脉综合征的应用及护理[J].内科,2010,(06):646.
 [J].Internal Medicine of China,2010,(06):646.
[10]李健,杨治平,张国盛,等.血栓通联合低分子肝素治疗高龄急性冠脉综合征介入治疗术后患者临床分析[J].内科,2016,(01):16.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.01.06]
 LI jian,YANG Zhi-ping,ZHANG Guo-sheng,et al.Clinical analysis of thrombus clear combined with low molecular heparin in treating elderly patients with acute coronary syndrome after percutaneous coronary intervention treatment[J].Internal Medicine of China,2016,(06):16.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2016.01.06]

备注/Memo

备注/Memo:
▲基金项目:河南省科技攻关计划项目(201702333)
更新日期/Last Update: 2021-01-11